

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(stock code: 2552)**

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF  
BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of Hua medicine (the “**Company**”) hereby announces that with effect from March 23, 2026, the address of the principal place of business in Hong Kong of the Company will be relocated from Unit 506, Hang Seng Wanchai Building, 200 Hennessy Road, Wanchai, Hong Kong to:

**Suite 1701, 8 Queen’s Road East, Wanchai, Hong Kong**

By Order of the Board

**Hua Medicine**

**Dr. Li Chen**

*Chief Executive Officer and Executive Director*

Hong Kong, March 23, 2026

*As at the date of this announcement, the Board comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.*